As GLP-1 receptor agonists continue expanding across obesity, diabetes, fatty liver disease, and cardiometabolic care, clinicians are increasingly confronting a pressing question: Does long-term use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results